Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Larotrectinib - Bayer/Loxo Oncology

Next Previous
Drug Profile

Larotrectinib - Bayer/Loxo Oncology

Alternative Names: AR-470; ARRY-470; BAY 2757556; Larotrectinib sulfate - Bayer/Loxo Oncology; LOXO 101; VITRAKVI

Latest Information Update: 30 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Array BioPharma
  • Developer Bayer; Loxo Oncology; National Cancer Institute (USA)
  • Class Amides; Antineoplastics; Fluorobenzenes; Pyrazoles; Pyrimidines; Pyrrolidines; Small molecules; Tumour-agnostic therapies
  • Mechanism of Action TrkA receptor antagonists; TrkB receptor antagonists; TrkC receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Solid tumours; Soft tissue sarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Solid tumours
  • Phase II Histiocytosis; Non-Hodgkin's lymphoma
  • Phase I/II CNS cancer

Most Recent Events

  • 17 Oct 2025 Updated pooled efficacy and adverse events data from a phase I trial, phase I/II SCOUT trial and the phase II NAVIGATE in Solid tumors presented at the 50th European Society for Medical Oncology Congress (ESMO-2025)
  • 29 Sep 2025 Loxo Oncology in collaboration with Bayer completes a phase II NAVIGATE basket trial in Solid tumours in US, Denmark, France, Japan, Norway, China, Czech Republic, Slovakia, Hungary, Sweden, Belgium, South Korea, Singapore, Spain, Portugal, Ireland, Argentina, Australia, Brazil, Canada, Germany, India, Italy, Poland, Russia, Taiwan, Turkey (NCT02576431) (EudraCT2015-003582-28)
  • 10 Dec 2024 Efficacy and adverse events data from a phase II NAVIGATE trial and phase I/II SCOUT trail in Breast cancer were presented at the 47th Annual San Antonio Breast Cancer Symposium (SABCS-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top